Fox Chase Cancer Center News

'Synthetic Lethality' Strategy Improves Molecularly Targeted Cancer Therapy

PHILADELPHIA (September 21, 2010) – Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them—but only if it was the right second agent.

VIEW STORY

Fox Chase Researchers Uncover Activation Signal for Aurora-A Oncogene: Discovery May Lead to More Potent Drug Combinations

PHILADELPHIA (September 7, 2010) - Aurora-A kinase (AurA) is an enzyme that is hyperactive in many cancers and drives tumor cell proliferation. Several AurA inhibitors are currently being tested in clinical trials to see if they slow tumor growth. Now, researchers in the Developmental Therapeutics Program at Fox Chase Cancer Center have identified an activation signal for AurA. 

VIEW STORY

Rectal Cancer Rates Are Rising in Young Individuals

PHILADELPHIA (August 23, 2010) –A new analysis has found that while colon cancer rates have remained steady over the past several decades among people under the age of 40, rectal cancer rates are increasing in this population across races and in both sexes. 

VIEW STORY

First-Ever BreastFest Philly to Benefit Fox Chase Cancer Center

PHILADELPHIA (August 19, 2010)—Enjoy a great day filled with food and drink, live music, games, silent auction, and more as The Tyanna Foundation hosts the first-ever BreastFest Philadelphia on Saturday, September 11 from 1-6 p.m. at City Tap House (3925 Walnut St., Philadelphia, PA 19104). 

VIEW STORY